ReviewImmunity, inflammation and disease2025
Molecular Mechanism of NLRP3 Inflammasome in Inflammatory Diseases and Tumors.
Review in Immunity, inflammation and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Exercise-Induced Exerkines: Multi-Nodal Suppression of the NLRP3 Inflammasome and Translational Potential.Medicinal research reviews · 2026Review
- Review
- Mitochondrial Dysfunction as a Driver of Neurodegeneration in Parkinson's and Huntington's Disease: Molecular Insights and Emerging Interventions.Molecular neurobiology · 2026Review
- The role of the cGAS-STING pathway in male reproductive disorders.Molecular biology reports · 2026Review
- Review
- Iron-Inflammasome Crosstalk in Adipose Tissue: Unresolved Roles of NLRP3 and IL-1β in Metabolic Inflammation.International journal of molecular sciences · 2025Review
- NLRP3 and beyond: inflammasomes as central cellular hub and emerging therapeutic target in inflammation and disease.Frontiers in immunology · 2025Review
- Interplay of oxidative stress and Inflammasome activation and clinical indices in Parkinson's disease: insights from serum SIRT1, Nrf2, and NLRP3 levels and PDQ-39-a cross-sectional study.Frontiers in neuroscience · 2025Article
- Interleukin-1β Secretion by Macrophages in Patients with Colorectal Cancer in Relation to the Clinicopathological Characteristics of the Disease.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The nucleotide-binding and oligomerization domain-like receptors (NLRs) are pattern recognition receptors. Nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing 3 (NLRP3), a member of the NLRs family, can form a protein complex with caspase-1, apoptosis-associated speck-like protein and caspase recruitment domain. And its assembly and activation cause inflammatory reaction and are closely related to the effects of antitumor immunity. The activation of NLRP3 inflammasome can induce polarization, hyperactivity or pyroptosis of immune cells, releasing interleukin-1β (IL-1β) and interleukin-18, which leads a cascade immunity or inflammatory responses. As an important component of the innate immune system, the NLRP3 inflammasome plays vital roles inflammatory diseases and tumors. In this review, we attempt to summarize the recent findings about the role of NLRP3 in the pathogenesis of tumors and inflammatory diseases such as diabetes, Alzheimer disease, and atherosclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.